RYALTRIS is a fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular, in one easy-to-use nasal spray
_256_384.jpg){kind=logo}
Veda Corporate Advisors was the exclusive financial advisor to SHPL and its shareholders.
The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA
Therapy recently approved in Canada under the brand name KORSUVA
The new subsidiary follows the recent announcement of Tetra's partnership with Cannvalate Pty Ltd for the performance of clinical trials of Tetra's drug candidates in Australia.
Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
New Covid-19 Medriva Rapid Antigen Test kits with very high- sensitivity now available in Australia
Novel technology combines ACUVUE daily disposable contact lenses with an established antihistamine in FDA- first in its new category
Subscribe To Our Newsletter & Stay Updated
